ALMS
Alumis Inc. Common Stock
NASDAQ · Healthcare · Biotechnology · US
$11.08
−2.46%Year over year
Reported trailing growth
- Revenue
- -63.1%
- EBITDA
- -8.1%
- EBIT
- -4.5%
- EPS
- +15.7%
- Free cash flow
- -1.4%
- Operating cash flow
- -1.8%
Forward estimates
Based on analyst estimates
- Revenue
- -28.4%
- EBITDA
- +17.8%
- EPS
- +24.3%
Three-year CAGR
- Revenue
- —
- EBITDA
- +14.7%
- EBIT
- -42.0%
- Net income
- +17.3%
- EPS
- +77.6%
- Free cash flow
- -44.1%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026